AMD

VABYSMO is the first treatment for wet AMD and DME in Canada that acts by targeting both VEGF-A and Ang-2, two key drivers of vascular instability that have been associated with vision-threatening retinal conditions.

The day helps to bring focus and awareness to risk factors for early vision loss associated with smoking.

The iPredict AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.

The company is currently developing treatments for age related macular degeneration as injections and eye drops, among others.

According to the company, topical administration is capable of delivering metformin to choroid, RPE, and retina.

The iPredictTM AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.

PMC-403 is a first-in-class antibody that activates TIE2, a receptor specifically expressed in vascular endothelial cells. The clinical trial will take place in multiple hospitals in South Korea.

AIV007 is a broad spectrum tyrosine kinase inhibitor, targeting the convergence of fibrosis, angiogenesis, and inflammation.

The two companies have announced an exclusive agreement for Polifarma to commercialize AVT06, the proposed biosimilar to Eylea, in Turkey.

Leo P. Semes, OD, shared his insights on early detection of age-related macular degeneration during the 17th annual Controversies in Modern Eye Care symposium in Los Angeles, California.

Espansione Group announced the second wave of its major research effort for the prevention and management of dry AMD.

If approved, RVO would be the third indication for Vabysmo in addition to wet age-related macular degeneration and diabetic macular edema.

The treatment is designed to slow the rate of degeneration of retinal cells, slowing the progression of geographic atrophy.

Researchers collaborate to study AMD through database of donor eye tissue to provide new data for study and future treatment targeting.

Alvin Liu, MD, sat down with Sheryl Stevenson, Group Editorial Director, Ophthalmology Times®, to discuss his presentation on deep learning and 3D OCT at the ASCRS annual meeting in San Diego.

Researchers in Australia have identified genes that play a role in oxidative stress and aging in the macula.

David Hutton from Ophthalmology Times and Jay Duker talk about wet AMD and the burdens of treatment on patients thanks to the consistent need for follow-ups and more.

Efavirenz boosts cholesterol turnover in retina, brain.

Ophthalmology Times® talked with Andrew Moshfeghi, MD, MBA, about OTX-TKI in a phase 1 study looking at patients with neovascular AMD this year's ARVO meeting.

Ophthalmology Times® talked with David Tabano, PhD, from Genentech about the company's first real-world data readouts for faricimab in the treatment of DME at this year's ARVO meeting.

Photobiomodulation is an emerging treatment for dry age-related macular degeneration (AMD).

Ophthalmology Times® talked with Allen Chiang, MD, about the assessment of geographic atrophy progression from the Phase 3 OAKS and DERBY trials at this year's ARVO meeting.

Ophthalmology Times® talked with Kaushal Solanki, PhD, CEO and founder of Eyenuk, about EyeArt, an AI system cleared by the FDA to detect diabetic retinopathy at this year's ARVO meeting.

D-4517.2 is a novel precision nanomedicine that inhibits neovascularization by targeting activated microglia and hypertrophic retinal pigment cells, cells responsible for the increased vascularization associated with neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Genentech announced post-hoc data indicating treatment with faricimab-svoa (Vabysmo) led to greater and faster drying of retinal fluid with fewer injections for the treatments of wet AMD and DME, when compared to aflibercept.